Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096494 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
A Phase 2 study, sponsored by Scilex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT05096494 is a Phase 2 study that has completed, run by Scilex Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT05096494, a Phase 2 study, has completed, sponsored by Scilex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.
Interventions
- DRUG Placebo
- DRUG SP-103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096494
The ClinicalTrials.gov registry entry for NCT05096494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scilex Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05096494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096494 about?
NCT05096494 is a clinical study titled "Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain". This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.
What is the current status of trial NCT05096494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2022-04-29. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT05096494?
The interventions under investigation include: Placebo (DRUG), SP-103 (DRUG).
Who is sponsoring clinical trial NCT05096494?
This trial is sponsored by Scilex Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.